Vancouver General Hospital

Summary

Vancouver General Hospital is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Stroke, Heart Attack, Atrial Fibrillation, Cancer, Heart Failure and other specialties. Vancouver General Hospital is involved with conducting 290 clinical trials across 467 conditions. There are 30 research doctors associated with this hospital, such as David A Wood, MD, Jacqueline Saw, MD, Ben Chew, MD, and Thalia Field, MD.

Top PIs

Clinical Trials running at Vancouver General Hospital

Stroke

Atrial Fibrillation

Chronic Obstructive Pulmonary Disease

Idiopathic Pulmonary Fibrosis

Heart Attack

Obesity

Non-Hodgkin's Lymphoma

Acute Lymphoblastic Leukemia

Coronary Artery Dissection

Coronary Artery Disease

Blood Thinners

for Atrial Fibrillation

This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.

Recruiting

3 awards

Phase 4

4 criteria

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.

Recruiting

1 award

Phase 3

2 criteria

Milvexian

for Stroke

This trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.

Recruiting

1 award

Phase 3

5 criteria